

## DAFTAR PUSTAKA

Ambrose, D. *et al.* (1994) 'Growth regulation of human glioblastoma T98G cells by insulin-like growth factor-1 and its receptor', *Journal of Cellular Physiology*, 1994 Apr;159(1):92-100. Available at: <https://doi.org/10.1002/jcp.1041590113>.

Baan, R. *et al.* (2011) 'Carcinogenicity of radiofrequency electromagnetic fields', *The Lancet Oncology*, 12(7), pp. 624–626. Available at: [https://doi.org/10.1016/s1470-2045\(11\)70147-4](https://doi.org/10.1016/s1470-2045(11)70147-4).

Bondy, M.L. *et al.* (2008) 'Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium', *Cancer*, 113(7), pp. 1953–1968. Available at: <https://doi.org/10.1002/cncr.23741>.

Chakravarti, A. *et al.* (2006) 'Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms', *Clinical Cancer Research*, 12(15), pp. 4738–4746. Available at: <https://doi.org/10.1158/1078-0432.CCR-06-0596>.

Christians, A. *et al.* (2012) 'Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma', *PLoS ONE*, 7(3). Available at: <https://doi.org/10.1371/journal.pone.0033449>.

Cohen, A.L., Holmen, S.L. and Colman, H. (2013) 'IDH1 and IDH2 mutations in gliomas', *Current Neurology and Neuroscience Reports*, 13(5). Available at: <https://doi.org/10.1007/s11910-013-0345-4>.

Cowppli-Bony, A. *et al.* (2011) 'Brain tumors and hormonal factors: Review of the epidemiological literature', *Cancer Causes and Control*, 22(5), pp. 697–714. Available at: <https://doi.org/10.1007/s10552-011-9742-7>.

Daumas-Duport, C. *et al.* (1988) 'Grading of astrocytomas: A simple and reproducible method', *Cancer*, 62(10), pp. 2152–2165. Available at: [https://doi.org/10.1002/1097-0142\(19881115\)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T](https://doi.org/10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T).

Drabycz, S. *et al.* (2010) 'An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging', *NeuroImage*, 49(2), pp. 1398–1405. Available at: <https://doi.org/10.1016/j.neuroimage.2009.09.049>.

Ellingson, B.M. *et al.* (2012) 'Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A

radiographic study in 358 de novo human glioblastomas', *NeuroImage*, 59(2), pp. 908–916. Available at: <https://doi.org/10.1016/j.neuroimage.2011.09.076>.

Ellingson, B.M. *et al.* (2013) 'Probabilistic radiographic atlas of glioblastoma phenotypes', *AJNR Am J Neuroradiol*, 34:533-540. Available at: <https://doi.org/10.3174/ajnr.A3253>.

Eoli, M. *et al.* (2007) 'Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival', *Clinical Cancer Research*, 13(9), pp. 2606–2613. Available at: <https://doi.org/10.1158/1078-0432.CCR-06-2184>.

Esteller, M. *et al.* (1999) "Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia," *Cancer Res* 1999;59:793e797. PMID: 10029064.

Esteller, M. *et al.* (2000) "Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents," *The New England Journal of Medicine*, Med2000;343:1350e1354. Available at: <https://doi.org/10.1056/NEJM200011093431901>

Everhard, S. *et al.* (2006) 'MGMT methylation: A marker of response to temozolomide in low-grade gliomas', *Annals of Neurology*, 60(6), pp. 740–743. Available at: <https://doi.org/10.1002/ana.21044>.

Felsberg, J. *et al.* (2011) 'Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas', *International Journal of Cancer*, 129(3), pp. 659–670. Available at: <https://doi.org/10.1002/ijc.26083>.

Fu, Y. *et al.* (2010) 'Glioma-derived mutations in IDH: from mechanism to potential therapy', *Biochem Biophys Res Commun*, 2010 Jun 25;397(2):127-30. Available at: <https://doi.org/10.1016/j.bbrc.2010.05.115>.

Fyllingen, E.H. *et al.* (2021) 'Survival of glioblastoma in relation to tumor location: a statistical tumor atlas of a population-based cohort', *Acta Neurochir (Wien)*, 2021; 163(7): 1895–1905. Available at: <https://doi.org/10.1007/s00701-021-04802-6>.

Gladson, C.L., Prayson, R.A. and Liu, W.M. (2010) 'The pathobiology of glioma tumors', *Annual Review of Pathology: Mechanisms of Disease*, 5(Cmv), pp. 33–50. Available at: <https://doi.org/10.1146/annurev-pathol-121808-102109>.

Gorlia, T. *et al.* (2008) 'Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial

26981-22981/CE.3', *Lancet Oncol*, 9(1), pp. 29–38. Available at: <https://doi.org/10.1016/S1470>.

Han, Y. *et al.* (2018) 'Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: A region of interest based analysis', *BMC Cancer*, 18(1), pp. 1–10. Available at: <https://doi.org/10.1186/s12885-018-4114-2>.

Hanif, F. *et al.* (2017) 'Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment', *Asian Pacific Journal of Cancer Prevention*, 18 (1), 3-9. Available at: <https://doi.org/10.22034/APJCP.2017.18.1.3>.

Hardell, L., Carlberg, M. and Mild, K.H. (2011) 'Pooled analysis of case-control studies on malignant brain tumours and the use of mobile and cordless phones including living and deceased subjects', *International Journal of Oncology*, 38(5), pp. 1465–1474. Available at: <https://doi.org/10.3892/ijo.2011.947>.

Håvik, A.B. *et al.* (2012) 'MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR', *Journal of Translational Medicine*, 10(1). Available at: <https://doi.org/10.1186/1479-5876-10-36>.

Hegi, M.E. *et al.* (2004) 'Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide', *Clinical Cancer Res*, 2004 Mar 15;10(6):1871-4. Available at: <https://doi.org/10.1158/1078-0432.ccr-03-0384>.

Hegi, Monika E. *et al.* (2005) 'MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma ', *New England Journal of Medicine*, 352(10), pp. 997–1003. Available at: <https://doi.org/10.1056/nejmoa043331>.

Horbinski, C., McCortney, K. and Stupp, R. (2021) 'MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas', *Neuro-Oncology*, 23(5), 858–860. Available at: <https://doi.org/10.1093/neuonc/noab039>.

Houillier, C. *et al.* (2010) 'IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas', *Neurology*, 2010 Oct 26;75(17):1560-6. Available at: <https://doi.org/10.1212/WNL.0b013e3181f96282>.

Huang, J. *et al.* (2019) 'Isocitrate dehydrogenase mutations in glioma: From basic discovery to therapeutics development', *Frontiers in Oncology*, 9(JUN). Available at: <https://doi.org/10.3389/fonc.2019.00506>.

July, J. *et al.* (2020) 'Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions

in high-grade glioma treated with standard treatment', *Pan Afr Med J*, 2020;36:309. Available at: <https://doi.org/10.11604/pamj.2020.36.309.24831>.

Kaina, B. *et al.* (2007) 'MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents', *DNA Repair*, 2007;6:1079–1099. Available at: <https://doi.org/10.1016/j.dnarep.2007.03.008>.

Kickingereder, P. *et al.* (2016) 'Radiogenomics of glioblastoma: Machine learning-based classification of molecular characteristics by using multiparametric and multiregional MR imaging features', *Radiology*, 281(3), pp. 907–918. Available at: <https://doi.org/10.1148/radiol.2016161382>.

Kim, Y.S. *et al.* (2012) 'MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: A single-institution study', *International Journal of Radiation Oncology Biology Physics*, 84(3), pp. 661–667. Available at: <https://doi.org/10.1016/j.ijrobp.2011.12.086>.

Kloosterhof, N.K. *et al.* (2011) 'Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?', *Lancet Oncol*, 2011 Jan;12(1):83-91. Available at: [https://doi.org/10.1016/S1470-2045\(10\)70053-X](https://doi.org/10.1016/S1470-2045(10)70053-X).

Lai, A. *et al.* (2011) 'Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin', *J Clin Oncol*, 29:4482–4490. Available at: <https://doi.org/10.1200/JCO.2010.33.8715>.

Lakomy, R. *et al.* (2011) 'MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients', *Cancer Science*, 102(12), pp. 2186–2190. Available at: <https://doi.org/10.1111/j.1349-7006.2011.02092.x>.

Lapointe, S., Perry, A. and Butowski, N.A. (2018) 'Primary brain tumours in adults', *The Lancet*, 392(10145), pp. 432–446. Available at: [https://doi.org/10.1016/S0140-6736\(18\)30990-5](https://doi.org/10.1016/S0140-6736(18)30990-5).

Larjavaara, S. *et al.* (2007) 'Incidence of gliomas by anatomic location', *Neuro-Oncology*, 9(3), pp. 319–325. Available at: <https://doi.org/10.1215/15228517-2007-016>.

Lee, J.H. *et al.* (2007) 'Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP<sup>+</sup>-dependent isocitrate dehydrogenase', *J Biol Chem*, 2007 May 4;282(18):13385-94. Available at: <https://doi.org/10.1074/jbc.M700303200>.

Li, H. *et al.* (2016) 'IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme

patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy’, *Clinical Neurology and Neurosurgery*, 151, pp. 31–36. Available at: <https://doi.org/10.1016/j.clineuro.2016.10.004>.

Liu, Y. *et al.* (2009) ‘Association and interactions between DNA repair gene polymorphisms and adult glioma’, *Cancer Epidemiology Biomarkers and Prevention*, 18(1), pp. 204–214. Available at: <https://doi.org/10.1158/1055-9965.EPI-08-0632>.

Louis, D.N. (2006) ‘Molecular pathology of malignant gliomas’, *Annual Review of Pathology*, 1, pp. 97–117. Available at: <https://doi.org/10.1146/annurev.pathol.1.110304.100043>.

Louis, D.N. *et al.* (2007) ‘The 2007 WHO classification of tumours of the central nervous system’, *Acta Neuropathologica*, 114(2), pp. 97–109. Available at: <https://doi.org/10.1007/s00401-007-0243-4>.

Louis, D.N. *et al.* (2016) ‘The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary’, *Acta Neuropathologica*, 131(6), pp. 803–820. Available at: <https://doi.org/10.1007/s00401-016-1545-1>.

Malmström, A. *et al.* (2012) ‘Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial’, *Lancet Oncol*, 2012;13(9):916–926. Available at: [https://doi.org/10.1016/S1470-2045\(12\)70265-6](https://doi.org/10.1016/S1470-2045(12)70265-6).

Malueka, R.G. *et al.* (2020) ‘Clinicopathological features and prognosis of Indonesian patients with gliomas with IDH mutation: Insights into its significance in a Southeast Asian population’, *Asian Pacific Journal of Cancer Prevention*, 21(8), pp. 2287–2295. Available at: <https://doi.org/10.31557/APJCP.2020.21.8.2287>.

Mansouri, A. *et al.* (2019) ‘MGMT promoter methylation status testing to guide therapy for glioblastoma: Refining the approach based on emerging evidence and current challenges’, *Neuro-Oncology*, 21(2), pp. 167–178. Available at: <https://doi.org/10.1093/neuonc/noy132>.

Ohba, S. *et al.* (2014) ‘Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance’, *Cancer Research*, 2014;74:4836–44. Available at: <https://doi.org/10.1158/0008-5472.CAN-14-0924>.

Ohgaki, H. and Kleihues, P. (2005) ‘Epidemiology and etiology of gliomas’, *Acta Neuropathologica*, 109(1), pp. 93–108. Available at: <https://doi.org/10.1007/s00401-005-0991-y>.

Ostrom, Q.T. *et al.* (2015) 'CBTRUS statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012', *Neuro-Oncology*, 17, pp. iv1–iv62. Available at: <https://doi.org/10.1093/neuonc/nov189>.

Ostrom, Q.T. *et al.* (2020) 'CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017', *Neuro-Oncology*, 22(Supplement\_1), pp. IV1–IV96. Available at: <https://doi.org/10.1093/neuonc/noaa200>.

Paldor, I. *et al.* (2016) 'Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors', *Journal of Clinical Neuroscience*, 2016 Dec;34:128-132. Available at: <https://doi.org/10.1016/j.jocn.2016.05.017>.

Pandith, A.A. *et al.* (2010) 'Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma', *Future Sci OA*, 2020;7(3):FSO663. Available at: <https://doi.org/10.2144/fsoa-2020-0057>.

Pegg, A.E. (2000) 'Repair of O6-alkylguanine by alkyltransferases', *Mutation Research - Reviews in Mutation Research*, 462(2–3), pp. 83–100. Available at: [https://doi.org/10.1016/S1383-5742\(00\)00017-X](https://doi.org/10.1016/S1383-5742(00)00017-X).

Perry, J.R. *et al.* (2017) 'Short-course radiation plus temozolomide in elderly patients with glioblastoma', *N Engl J Med*, 2017 Mar 16;376(11):1027-1037. Available at: <https://doi.org/10.1056/NEJMoa1611977>.

Poon, M.T.C. *et al.* (2021) 'Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study', *Neurooncol Adv*, 2021 Nov 19;3(1):vdab171. Available at: <https://doi.org/10.1093/oaajnl/vdab171>.

Rivera, A.L. *et al.* (2010) 'MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma', *Neuro-Oncology*, 12(2), pp. 116–121. Available at: <https://doi.org/10.1093/neuonc/nop020>.

Rubens, A.B., Mahowald, M.W., and Hutton, J.T. (1976) 'Asymmetry of the lateral (sylvian) fissures in man', *Neurology*, 1976 Jul;26(7):620-4. Available at: <https://doi.org/10.1212/wnl.26.7.620>.

Sanai, N., Mirzadeh, Z., and Berger, M.S. (2008) 'Functional outcome after language mapping for glioma resection', *N Engl J Med*, 358:18–27. Available at: <https://doi.org/10.1056/NEJMoa067819>.

Sanson, M. *et al.* (2009) 'Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas', *J Clin Oncol*, 2009 Sep 1;27(25):4150-4. Available at: <https://doi.org/10.1200/JCO.2009.21.9832>.

Sasaki, T. *et al.* (2019) 'Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma', *Scientific Reports*, 9(1). Available at: <https://doi.org/10.1038/s41598-019-50849-y>.

Smith, J.S. *et al.* (2000) 'Amplification of the platelet-derived growth factor receptor- $\alpha$  (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features', *Journal of Neuropathology and Experimental Neurology*, 59(6), pp. 495–503. Available at: <https://doi.org/10.1093/jnen/59.6.495>.

Stummer, W. *et al.* (2008) 'Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias', *Neurosurgery*, 62:564–576; discussion 564-576. Available at: <https://doi.org/10.1227/01.neu.0000317304.31579.17>.

Stupp, R. *et al.* (2009) 'Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial', *Lancet Oncol*, 2009 May;10(5):459-66. Available at: [https://doi.org/10.1016/S1470-2045\(09\)70025-7](https://doi.org/10.1016/S1470-2045(09)70025-7).

Sun, T. *et al.* (2005) 'Early asymmetry of gene transcription in embryonic human left and right cerebral cortex', *Science*, 308:1794-1798. Available at: <https://doi.org/10.1126/science.11110324>.

Sun, T. and Walsh, C.A. (2006) 'Molecular approaches to brain asymmetry and handedness', *Nature Reviews Neuroscience*, 2006;7:655–62. Available at: <https://doi.org/10.1038/nrn1930>.

Tanaka, K. *et al.* (2015) 'Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma', *Clinical Neurology and Neurosurgery*, 138, 37–44 (2015). Available at: <https://doi.org/10.1016/j.clineuro.2015.07.019>.

Tejada Neyra, M.A. *et al.* (2018) 'Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma', *Neuro-Oncology*, 20:1517–1524. Available at: <https://doi.org/10.1093/neuonc/noy134>.

Toga, A.W. and Thompson, P.M. (2003) 'Mapping Brain Asymmetry', *Nature Reviews Neuroscience*, 2003 Jan;4(1):37-48. Available at: <https://doi.org/10.1038/nrn1009>.

Thon, N. *et al.* (2011) 'Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide', *Journal of Neurology, Neurosurgery and Psychiatry*, 82(4), pp. 441–446. Available at: <https://doi.org/10.1136/jnnp.2010.214593>.

Thon, N., Kreth, S. and Kreth, F.W. (2013) 'Personalized treatment strategies in glioblastoma: MGMT promoter methylation status', *OncoTargets and Therapy*, 6, pp. 1363–1372. Available at: <https://doi.org/10.2147/OTT.S50208>.

Wang, P.F. *et al.* (2016) 'IDH-1R132H mutation status in diffuse glioma patients: implications for classification', *Oncotarget*, 2016;7(21):31393-31400. Available at: <https://doi.org/10.18632/oncotarget.8918>.

Weller, M. *et al.* (2010) 'MGMT promoter methylation in malignant gliomas: Ready for personalized medicine?', *Nature Reviews Neurology*, pp. 39–51. Available at: <https://doi.org/10.1038/nrneurol.2009.197>.

Weller, M. *et al.* (2015) 'MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial', *Clin. Cancer Res*, 2015;21:2057–2064. Available at: <https://doi.org/10.1158/1078-0432.CCR-14-2737>.

Wesseling, P. and Capper, D. (2018) 'WHO 2016 Classification of gliomas', *Neuropathology and Applied Neurobiology*, 44(2), pp. 139–150. Available at: <https://doi.org/10.1111/nan.12432>.

Wick, W. *et al.* (2012) 'NOA-08 Study Group of Neuro-Oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial', *Lancet Oncol*, 2012;13(7):707–715. Available at: [https://doi.org/10.1016/S1470-2045\(12\)70164-X](https://doi.org/10.1016/S1470-2045(12)70164-X).

Wick, W. *et al.* (2013) 'Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation', *American Academy of Neurology*, 2013;81:1515-1522. Available at: <https://doi.org/10.1212/WNL.0b013e3182a95680>.

Wick, W. *et al.* (2014) 'MGMT testing - The challenges for biomarker-based glioma treatment', *Nature Reviews Neurology*, 10(7), pp. 372–385. Available at: <https://doi.org/10.1038/nrneurol.2014.100>.

Widodo, D., Andriani, R. and Haq, I.B.I. (2019) 'Pedoman Nasional Pelayanan Kedokteran TUMOR OTAK', *Kemntrian kesehatan Republik Indonesia, Komite Penanggulangan Kanker Nasional*, 1, pp. 1–476.

Wiencke, J.K. *et al.* (2007) 'Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma', *Neuro-Oncology*, 9(3), pp. 271–279. Available at: <https://doi.org/10.1215/15228517-2007-003>.

Wrensch, M. *et al.* (2012) 'Epidemiology of primary brain tumors: Current concepts and review of the literature', *Tumors of the Central Nervous System, Volume 4: Brain Tumors (Part 2)*, pp. 3–13. Available at: [https://doi.org/10.1007/978-94-007-1706-0\\_1](https://doi.org/10.1007/978-94-007-1706-0_1).

Xu, Q. *et al.* (2008) 'Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas', *Stem Cells*, 2008;26:3018–26. Available at: <https://doi.org/10.1634/stemcells.2008-0459>.

Yaşargil, M.G., Kadri P.A., and Yaşargil, D.C. (2004) 'Microsurgery for malignant gliomas', *J Neuro-Oncol*, 69:67-81. Available at: <https://doi.org/10.1023/b:neon.0000041872.78927.d5>.

Yan, W. *et al.* (2012) 'Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China', *PLoS One*, 2012;7(1):e30339. Available at: <https://doi.org/10.1371/journal.pone.0030339>.

Yang, P. *et al.* (2015) 'IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry', *Oncotarget*, 2015;6(38):40896-40906. Available at: <https://doi.org/10.18632/oncotarget.5683>.

Zhang, C.B. *et al.* (2013) 'Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China', *J Cancer Res Clin*, 140, 45-51. Available at: <https://doi.org/10.1007/s00432-013-1519-9>.